<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439462</url>
  </required_header>
  <id_info>
    <org_study_id>COLO-007</org_study_id>
    <nct_id>NCT03439462</nct_id>
  </id_info>
  <brief_title>ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase 1/2 Multi-center Investigation of ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aadi, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aadi, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1/2 multi-center investigation of ABI-009 (nab-rapamycin) in combination with
      mFOLFOX6 and Bevacizumab as first-line therapy in patients with advanced or metastatic
      colorectal cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median PFS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-009; nab-rapamycin; albumin-bound rapamycin</intervention_name>
    <description>albumin-bound rapamycin</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed advanced or metastatic colorectal cancers for
             whom chemotherapy is indicated.

          2. Patients must not have had prior chemotherapy for advanced or metastatic disease.
             Patients could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy.

          3. Patients must have at least 1 measurable site of disease according to RECIST v1.1 that
             has not been previously irradiated. If the patient has had previous radiation to the
             marker lesion(s), there must be radiological evidence of progression since the
             radiation.

          4. Eligible patients, 18 years or older, with Eastern Cooperative Oncology Group (ECOG)
             performance status 0, 1, or 2.

          5. Patients must not have been previously treated with an mTOR inhibitor.

          6. Adequate liver function:

               1. Total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dL

               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN
                  (&lt;5 x ULN if the patient has liver metastases).

          7. Adequate renal function:

             a. Serum creatinine ≤2 x ULN or creatinine clearance &gt;50 cc/hr (Cockroft-Gault).

          8. Adequate biological parameters:

               1. Absolute neutrophil count (ANC) ≥1.5 × 109/L

               2. Platelet count ≥100,000/mm3 (100 × 109/L)

               3. Hemoglobin ≥9 g/dL.

          9. Fasting serum triglyceride ≤300 mg/dL; fasting serum cholesterol ≤350 mg/dL.

         10. INR and PTT &lt;1.5 x ULN (anticoagulation is allowed if target INR &lt;1.5 on a stable dose
             of warfarin or on a stable dose of LMW heparin for &gt;2 weeks at time of enrollment).

         11. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of
             all prior systemic anticancer therapy, and ≥6 months since adjuvant FOLFOX therapy
             (adequately recovered from the acute toxicities of any prior therapy, including
             neuropathy should be grade ≤1).

         12. Male or non-pregnant and non-breast feeding female:

               -  Females of child-bearing potential must agree to use effective contraception
                  without interruption from 28 days prior to starting IP throughout 3 months after
                  last dose of IP and have a negative serum pregnancy test (β -hCG) result at
                  screening and agree to ongoing pregnancy testing during the course of the study,
                  and after the end of study treatment. A second form of birth control is required
                  even if she has had a tubal ligation.

               -  Male patients must practice abstinence or agree to use a condom during sexual
                  contact with a pregnant female or a female of childbearing potential while
                  participating in the study and throughout 3 months after last dose of IP. A
                  second form of birth control is required even if he has undergone a successful
                  vasectomy.

         13. Life expectancy of &gt;3 months, as determined by the investigator.

         14. Ability to understand and sign informed consent.

         15. Willingness and ability to comply with scheduled visits, laboratory tests, and other
             study procedures.

        Exclusion Criteria:

          1. History of severe and uncontrolled allergic reactions to bevacizumab

          2. Prior treatment with FOLFOX or bevacizumab within the preceding 4 weeks

          3. Patients currently receiving or have received anticancer therapies within 4 weeks of
             the start of study treatment (including chemotherapy, radiation therapy, antibody
             based therapy, etc.)

          4. Patients, who have had a major surgery or significant traumatic injury within 4 weeks
             of start of study drug, patients who have not recovered from the side effects of any
             major surgery (defined as requiring general anesthesia) or patients that may require
             major surgery during the course of the study

          5. Chronic treatment with systemic steroids or another immunosuppressive agent; topical
             or inhaled corticosteroids are allowed

          6. Recent infection requiring systemic anti-infective treatment that was completed ≤14
             days prior to enrollment (with the exception of uncomplicated urinary tract infection
             or upper respiratory tract infection).

          7. Patients who have any severe and/or uncontrolled medical or psychiatric conditions or
             other conditions that could affect their participation including:

               1. Known active uncontrolled or symptomatic central nervous system (CNS) metastases.
                  A patient with controlled and asymptomatic CNS metastases may participate in this
                  study. As such, the patient must have completed any prior treatment for CNS
                  metastases ≥28 days (including radiotherapy and/or surgery) prior to start of
                  treatment in this study and should not be receiving chronic corticosteroid
                  therapy for the CNS metastases.

               2. Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac
                  arrhythmia or any other clinically significant cardiac disease

               3. Pre-existing severely impaired lung function as defined as spirometry and DLCO
                  that is 50% of the normal predicted value and/or O2 saturation that is 88% or
                  less at rest on room air (Note: spirometry and PFTs not required to be performed
                  unless clinically indicated).

               4. Uncontrolled diabetes as defined by fasting serum glucose &gt;1.5x ULN or by HbA1c
                  &gt;8% despite adequate therapy.

               5. Any active (acute or chronic) or uncontrolled infection/ disorders.

               6. Nonmalignant medical illnesses that are uncontrolled or whose control may be
                  jeopardized by the treatment with the study therapy. Note, controlled
                  non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental
                  prostate cancer, or other adequately treated carcinoma-in-situ may be eligible,
                  after documented discussion with the sponsor / medical monitor.

               7. Known liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh
                  class C).

          8. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary
             hypertension.

          9. A known history of HIV seropositivity.

         10. Active Hepatitis B or Hepatitis C. Note: A detailed assessment of Hepatitis B/C
             medical history and risk factors must be done at screening for all patients. HBV DNA
             and HCV RNA PCR testing are required at screening for all patients with a positive
             medical history based on risk factors and/or confirmation of prior HBV/HCV infection.

         11. Patients with an active bleeding diathesis or on oral anti-vitamin K medication
             (except low dose Coumadin).

         12. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving
             the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with
             narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,
             dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to
             receiving the first dose of ABI-009.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Berta Grigorian</last_name>
    <phone>818-416-8378</phone>
    <email>bgrigorian@aadibio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN RN AOCNS</last_name>
      <phone>480-323-1791</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Woolery</last_name>
      <phone>504-842-0275</phone>
      <email>Amanda.woolery@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Arlene SJ. Ramirez, RN, OCN</last_name>
      <phone>702-952-3406</phone>
      <email>anaarlene.ramirez@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System/Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Ginder</last_name>
      <phone>973-971-6608</phone>
      <email>Nancy.ginder@atlantichealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preethi Ravindranathan</last_name>
      <phone>214-820-8685</phone>
      <email>Preethi.Ravindranathan@BSWHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GI Research</last_name>
      <phone>206-606-6405</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>December 7, 2019</last_update_submitted>
  <last_update_submitted_qc>December 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

